Valneva makes U.S. regulatory submission for one-shot chikungunya vaccine By Reuters

PARIS (Reuters) – Vaccines firm Valneva stated on Friday that it had accomplished a regulatory submission step with america Meals & Drug Administration (FDA) for its single-shot chikungunya vaccine candidate, VLA1553.

Chikungunya is a mosquito-borne viral illness. Valneva plans to make regulatory submissions for its VLA1553 vaccine in Europe within the second half of 2023.